State to receive money from drug company

[Guest guest]

Of course this Warner-Lambert has been owned by Pfizer for several years now.

Wonder why that is not mentioned in the article.....

Copyright 2004 Bell & Howell Information and Learning

Business Dateline

Copyright 2004 The Missoulian

Missoulian

May 26, 2004

SECTION: Pg. B2

B & H-ACC-NO: 645902691

LENGTH: 365 words

HEADLINE: State to receive money from drug company

BODY:

HELENA - Montana will receive nearly $483,000 from pharmaceutical

manufacturer Parke- in restitution and penalty pay as part of a settlement

recently negotiated between the drug company and the National Association of

Medicaid Fraud Control Units.

But $331.000 of that must be credited back to the federal Medicaid program

since the federal government pays 75 percent of Montana's program costs,

resulting in a net gain of $152,000 for the state.

Parke-, a division of Warner-Lambert, will pay $152 million in damages

and penalties to Medicaid programs in 47 states and the District of Columbia as

part of an agreement that resolves allegations of a massive " offlabel " marketing

campaign for the epilepsy medication Neurontin.

" Off-label " describes a use of a medication other than the use for which the

drug is approved. Although doctors may prescribe drugs for off-label purposes,

it is illegal for manufacturers to promote those off-label uses.

The pharmaceutical company had allegedly marketed Neurontin for a variety of

off-label uses, including pain management, bipolar disorder, alcohol and drug

withdrawal and migraines.

Warner-Lambert also made payments to physicians for " research " that the

government contended was in effect a kickback for off-label prescribing, and

provided expensive perks to physicians who attended or spoke at the continuing

education classes where Neurontin was promoted for off-labeI uses.

This marketing campaign resulted in inappropriate, unnecessary and/or

ineffective prescriptions for Neurontin, which were in turned paid for by the

Medicaid program.

Payments to Montana include $74,368 in Medicaid restitution, $74,368 in

Medicaid penalties and $3,162.97 in interest. The funds are repaid to the

Montana Medicaid program administered by the state Department of Public Health

and Human Services.

The case was handled by the National Association of Medicaid Fraud Control

Units and the U.S. Department of Justice, based on investigations and data from

state Medicaid Fraud Control Units.

The Medicaid fraud settlement is separate from a recent consumer-protection

settlement with Warner-Lambert.

LOAD-DATE: June 15, 2004

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

Of course this Warner-Lambert has been owned by Pfizer for several years now.

Wonder why that is not mentioned in the article.....

Copyright 2004 Bell & Howell Information and Learning

Business Dateline

Copyright 2004 The Missoulian

Missoulian

May 26, 2004

SECTION: Pg. B2

B & H-ACC-NO: 645902691

LENGTH: 365 words

HEADLINE: State to receive money from drug company

BODY:

HELENA - Montana will receive nearly $483,000 from pharmaceutical

manufacturer Parke- in restitution and penalty pay as part of a settlement

recently negotiated between the drug company and the National Association of

Medicaid Fraud Control Units.

But $331.000 of that must be credited back to the federal Medicaid program

since the federal government pays 75 percent of Montana's program costs,

resulting in a net gain of $152,000 for the state.

Parke-, a division of Warner-Lambert, will pay $152 million in damages

and penalties to Medicaid programs in 47 states and the District of Columbia as

part of an agreement that resolves allegations of a massive " offlabel " marketing

campaign for the epilepsy medication Neurontin.

" Off-label " describes a use of a medication other than the use for which the

drug is approved. Although doctors may prescribe drugs for off-label purposes,

it is illegal for manufacturers to promote those off-label uses.

The pharmaceutical company had allegedly marketed Neurontin for a variety of

off-label uses, including pain management, bipolar disorder, alcohol and drug

withdrawal and migraines.

Warner-Lambert also made payments to physicians for " research " that the

government contended was in effect a kickback for off-label prescribing, and

provided expensive perks to physicians who attended or spoke at the continuing

education classes where Neurontin was promoted for off-labeI uses.

This marketing campaign resulted in inappropriate, unnecessary and/or

ineffective prescriptions for Neurontin, which were in turned paid for by the

Medicaid program.

Payments to Montana include $74,368 in Medicaid restitution, $74,368 in

Medicaid penalties and $3,162.97 in interest. The funds are repaid to the

Montana Medicaid program administered by the state Department of Public Health

and Human Services.

The case was handled by the National Association of Medicaid Fraud Control

Units and the U.S. Department of Justice, based on investigations and data from

state Medicaid Fraud Control Units.

The Medicaid fraud settlement is separate from a recent consumer-protection

settlement with Warner-Lambert.

LOAD-DATE: June 15, 2004

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

Of course this Warner-Lambert has been owned by Pfizer for several years now.

Wonder why that is not mentioned in the article.....

Copyright 2004 Bell & Howell Information and Learning

Business Dateline

Copyright 2004 The Missoulian

Missoulian

May 26, 2004

SECTION: Pg. B2

B & H-ACC-NO: 645902691

LENGTH: 365 words

HEADLINE: State to receive money from drug company

BODY:

HELENA - Montana will receive nearly $483,000 from pharmaceutical

manufacturer Parke- in restitution and penalty pay as part of a settlement

recently negotiated between the drug company and the National Association of

Medicaid Fraud Control Units.

But $331.000 of that must be credited back to the federal Medicaid program

since the federal government pays 75 percent of Montana's program costs,

resulting in a net gain of $152,000 for the state.

Parke-, a division of Warner-Lambert, will pay $152 million in damages

and penalties to Medicaid programs in 47 states and the District of Columbia as

part of an agreement that resolves allegations of a massive " offlabel " marketing

campaign for the epilepsy medication Neurontin.

" Off-label " describes a use of a medication other than the use for which the

drug is approved. Although doctors may prescribe drugs for off-label purposes,

it is illegal for manufacturers to promote those off-label uses.

The pharmaceutical company had allegedly marketed Neurontin for a variety of

off-label uses, including pain management, bipolar disorder, alcohol and drug

withdrawal and migraines.

Warner-Lambert also made payments to physicians for " research " that the

government contended was in effect a kickback for off-label prescribing, and

provided expensive perks to physicians who attended or spoke at the continuing

education classes where Neurontin was promoted for off-labeI uses.

This marketing campaign resulted in inappropriate, unnecessary and/or

ineffective prescriptions for Neurontin, which were in turned paid for by the

Medicaid program.

Payments to Montana include $74,368 in Medicaid restitution, $74,368 in

Medicaid penalties and $3,162.97 in interest. The funds are repaid to the

Montana Medicaid program administered by the state Department of Public Health

and Human Services.

The case was handled by the National Association of Medicaid Fraud Control

Units and the U.S. Department of Justice, based on investigations and data from

state Medicaid Fraud Control Units.

The Medicaid fraud settlement is separate from a recent consumer-protection

settlement with Warner-Lambert.

LOAD-DATE: June 15, 2004

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

Of course this Warner-Lambert has been owned by Pfizer for several years now.

Wonder why that is not mentioned in the article.....

Copyright 2004 Bell & Howell Information and Learning

Business Dateline

Copyright 2004 The Missoulian

Missoulian

May 26, 2004

SECTION: Pg. B2

B & H-ACC-NO: 645902691

LENGTH: 365 words

HEADLINE: State to receive money from drug company

BODY:

HELENA - Montana will receive nearly $483,000 from pharmaceutical

manufacturer Parke- in restitution and penalty pay as part of a settlement

recently negotiated between the drug company and the National Association of

Medicaid Fraud Control Units.

But $331.000 of that must be credited back to the federal Medicaid program

since the federal government pays 75 percent of Montana's program costs,

resulting in a net gain of $152,000 for the state.

Parke-, a division of Warner-Lambert, will pay $152 million in damages

and penalties to Medicaid programs in 47 states and the District of Columbia as

part of an agreement that resolves allegations of a massive " offlabel " marketing

campaign for the epilepsy medication Neurontin.

" Off-label " describes a use of a medication other than the use for which the

drug is approved. Although doctors may prescribe drugs for off-label purposes,

it is illegal for manufacturers to promote those off-label uses.

The pharmaceutical company had allegedly marketed Neurontin for a variety of

off-label uses, including pain management, bipolar disorder, alcohol and drug

withdrawal and migraines.

Warner-Lambert also made payments to physicians for " research " that the

government contended was in effect a kickback for off-label prescribing, and

provided expensive perks to physicians who attended or spoke at the continuing

education classes where Neurontin was promoted for off-labeI uses.

This marketing campaign resulted in inappropriate, unnecessary and/or

ineffective prescriptions for Neurontin, which were in turned paid for by the

Medicaid program.

Payments to Montana include $74,368 in Medicaid restitution, $74,368 in

Medicaid penalties and $3,162.97 in interest. The funds are repaid to the

Montana Medicaid program administered by the state Department of Public Health

and Human Services.

The case was handled by the National Association of Medicaid Fraud Control

Units and the U.S. Department of Justice, based on investigations and data from

state Medicaid Fraud Control Units.

The Medicaid fraud settlement is separate from a recent consumer-protection

settlement with Warner-Lambert.

LOAD-DATE: June 15, 2004

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss